BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Geisinger and Celera Diagnostics to Collaborate on Liver Disease Test


2/19/2008 7:52:46 AM

DANVILLE, Pa. & ALAMEDA, Calif.--(BUSINESS WIRE)--Geisinger Health System and Celera (NYSE:CRA), an Applera Corporation business, today announced that they have entered into a research collaboration with the aim of developing a diagnostic assay for the increased risk of non-alcoholic steatohepatitis (NASH). The collaboration will evaluate Celera’s numerous genetic findings in liver diseases, including the Cirrhosis Risk Score™, in the Geisinger bank of more than 600 liver tissue and blood case-control samples donated from patients who have undergone bariatric weight loss surgery. The Geisinger biorespository is among the largest of its kind within a research setting. Financial terms of this multi-year collaboration were not disclosed. Non-alcoholic fatty liver disease (NAFLD) is a condition where there is accumulation of excess fat in the liver. NAFLD is usually asymptomatic and, as a result, many people don’t know they have the condition until substantial liver damage has occurred. NASH represents an advanced stage of the disease when the accumulated fat results in significant inflammation and scarring. This occurs in approximately a quarter of the patients and can lead to cirrhosis. Ultimately, a liver transplant may be required. Knowledge of those individuals most likely to suffer from this advanced disease could enable closer monitoring of these individuals, leading to overall improved disease management.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES